In the midst of an unprecedented dealmaking spree that has produced $139 billion in pharmaceutical mergers this quarter alone, one country has been conspicuously absent: Japan. Even such giants as Astellas Pharma and Takeda Pharmaceutical, which have led M&A runs in Japan in the past, have stayed on the sidelines. Why?
written on 10.06.2014
Japanese companies follow Sanofi's lead in shunning Big Pharma M&A trend
